FDAnews
www.fdanews.com/articles/147079-fda-approves-glaxo-xenoport-drug-horizant-for-shingles-related-disease

FDA Approves Glaxo, XenoPort Drug Horizant For Shingles-Related Disease

June 8, 2012
The U.S. Food and Drug Administration has approved Horizant, a drug developed and marketed by GlaxoSmithKline and XenoPort for the management of postherpetic neuralgia, a nerve disease that sometimes follows shingles.
The Wall Street Journal